Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may foretell kidney trouble in lupus

NCT ID NCT07780045

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study looks at whether two blood-based inflammation markers, called SII and SIRI, can help track disease activity and predict kidney flares in people with lupus nephritis, a type of kidney inflammation caused by lupus. Researchers will follow 100 adults with confirmed lupus nephritis, measuring these markers and comparing them with standard measures of disease activity and kidney function. The goal is to see if these simple, inexpensive tests could serve as early warning signs for kidney problems, helping doctors intervene sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If these blood markers prove reliable, they could offer a simple way to monitor lupus nephritis and predict kidney flares, potentially improving early treatment decisions.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The markers may not be specific enough, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with lupus nephritis attending the Internal Medicine Department (Nephrology and Rheumatology units) at Assiut University Hospitals who meet the study eligibility criteria.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria * Confirmed lupus nephritis according to ISN/RPS classification Exclusion Criteria: * Active infection, sepsis, or other concurrent inflammatory or autoimmune conditions * Malignancy or hematologic disorders affecting blood cell counts * Pregnancy * Use of medications significantly affecting blood counts (such as recent chemotherapy or G-CSF) * Incomplete medical records or anticipated loss to follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney disorder lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney diseases Lupus nephritis Systemic lupus erythematosus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.